Dataset from Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00008330
下载链接
链接失效反馈官方服务：
资源简介：
This study will evaluate the anti-cancer effects of crizotinib when compared with standard
chemotherapy in patients with ALK positive lung cancer.
创建时间：
2025-09-25
